Jiangnan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiangnan Zhao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kai Wang
University of Pennsylvania
2 shared publications - Dongqing Lv
Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Linhai City, Taizhou, China
1 shared publication Hai Song
1 shared publicationJiaji Wu
1 shared publicationJianghao Yu
1 shared publication- Lei Xu
Institute of Materials Research, Division for Metallic Biomaterials, Helmholtz-Zentrum Geesthacht (HZG), Geesthacht, Germany
1 shared publication
Latest Publications
- Open Access
- 5 June 2026
- Published by Elsevier in SSRN Electronic Journal
CXCL12+ CAF and SPP1+ TAM Form a Stroma-Myeloid Niche Driving TME Heterogeneity in COPD-Associated Lung Cancer
Background: The widespread occurrence of chronic obstructive pulmonary disease (COPD) significantly complicates the management of lung cancer (LC). Patients suffering from both LC and COPD generally have a poor prognosis and limited effectiveness from conventional therapies, yet they often respond well to immunotherapy. This study aims to characterize the unique tumor microenvironment (TME) of COPD-associated LC (COPD-LC) using multi-omics approaches and to elucidate the mechanisms influencing immunotherapy efficacy.Methods: We performed single‑cell RNA sequencing on tumor and adjacent normal tissues from 11 non‑small cell lung cancer patients (6 with COPD, 5 without), generating a single‑cell atlas of >200,000 cells. These data were integrated with spatial transcriptomics, mass spectrometry‑based proteomics, TCGA data mining, and functional in vitro experiments to systematically map the TME cellular landscape, cell‑cell interactions, and immune regulatory mechanisms in COPD-LC.Findings: Our research identified a distinct subset of CXCL12+ cancer-associated fibroblasts (CAFs) characterized by a heightened stromal signature. These specialized CAFs mediate immunosuppressive effects within the tumor microenvironment of LC patients with comorbid COPD through CXCL12-CXCR4 axis-mediated modulation of CD8+ T cell function. Spatial transcriptomics and multiplex immunofluorescence confirmed colocalization of CXCL12⁺ CAFs with CXCR4⁺ CD8⁺ T cells. SPP1⁺ tumor‑associated macrophages (TAMs) were significantly less abundant in COPD-LC compared to non‑COPD-LC, and this reduction was regulated by the hypoxia‑SPI1 signaling axis. SPP1⁺ TAMs promoted terminal exhaustion of CD8⁺ T cells, whereas in COPD patients CD8⁺ T cells remained in a more progenitor exhaustion state. In vitro assays demonstrated that CXCL12 reduced CD8⁺ T cell effector function (decreased TNF‑α, IFN‑γ, GZMB), while SPP1 upregulated exhaustion markers (PD‑1, TIM‑3) on CD8⁺ T cells.Interpretation: Our results highlight the specific characteristics of the TME that are linked to poor prognosis and altered sensitivity to immunotherapy in COPD-LC, offering a basis for prioritizing treatment strategies to improve therapeutic outcomes.
- 5 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCXCL12+ CAF and SPP1+ TAM Form a Stroma-Myeloid Niche Driving TME Heterogeneity in COPD-Associated Lung Cancer
Background: The widespread occurrence of chronic obstructive pulmonary disease (COPD) significantly complicates the management of lung cancer (LC). Patients suffering from both LC and COPD generally have a poor prognosis and limited effectiveness from conventional therapies, yet they often respond well to immunotherapy. This study aims to characterize the unique tumor microenvironment (TME) of COPD-associated LC (COPD-LC) using multi-omics approaches and to elucidate the mechanisms influencing immunotherapy efficacy.Methods: We performed single‑cell RNA sequencing on tumor and adjacent normal tissues from 11 non‑small cell lung cancer patients (6 with COPD, 5 without), generating a single‑cell atlas of >200,000 cells. These data were integrated with spatial transcriptomics, mass spectrometry‑based proteomics, TCGA data mining, and functional in vitro experiments to systematically map the TME cellular landscape, cell‑cell interactions, and immune regulatory mechanisms in COPD-LC.Findings: Our research identified a distinct subset of CXCL12+ cancer-associated fibroblasts (CAFs) characterized by a heightened stromal signature. These specialized CAFs mediate immunosuppressive effects within the tumor microenvironment of LC patients with comorbid COPD through CXCL12-CXCR4 axis-mediated modulation of CD8+ T cell function. Spatial transcriptomics and multiplex immunofluorescence confirmed colocalization of CXCL12⁺ CAFs with CXCR4⁺ CD8⁺ T cells. SPP1⁺ tumor‑associated macrophages (TAMs) were significantly less abundant in COPD-LC compared to non‑COPD-LC, and this reduction was regulated by the hypoxia‑SPI1 signaling axis. SPP1⁺ TAMs promoted terminal exhaustion of CD8⁺ T cells, whereas in COPD patients CD8⁺ T cells remained in a more progenitor exhaustion state. In vitro assays demonstrated that CXCL12 reduced CD8⁺ T cell effector function (decreased TNF‑α, IFN‑γ, GZMB), while SPP1 upregulated exhaustion markers (PD‑1, TIM‑3) on CD8⁺ T cells.Interpretation: Our results highlight the specific characteristics of the TME that are linked to poor prognosis and altered sensitivity to immunotherapy in COPD-LC, offering a basis for prioritizing treatment strategies to improve therapeutic outcomes.
- 22 August 2025
- Published by Elsevier in Cancer Letters
- Vol. 633, 218000
Proteomics and single cell profiling identify keratin driven preexisting immunity influences lung squamous carcinoma neoadjuvant therapy
- 22 August 2025
- Published by Elsevier in Cancer Letters
- Vol. 633, 218000
Proteomics and single cell profiling identify keratin driven preexisting immunity influences lung squamous carcinoma neoadjuvant therapy